{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:41:14Z","timestamp":1793166074018,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The biological mechanisms underlying the differential response to abatacept in patients with rheumatoid arthritis (RA) are unknown. Here, we aimed to identify cellular, transcriptomic, and proteomic features that predict resistance to abatacept in patients with RA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Blood samples were collected from 22 RA patients treated with abatacept at baseline and after 3\u00a0months of treatment. Response to treatment was defined by the European League Against Rheumatism (EULAR) response criteria at 3\u00a0months, and seven patients were classified as responders and the others as non-responders. We quantified gene expression levels by RNA sequencing, 67 plasma protein levels, and the expression of surface molecules (CD3, 19, and 56) by flow cytometry. In addition, three gene expression data sets, comprising a total of 27 responders and 50 non-responders, were used to replicate the results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the clinical characteristics, the number of monocytes was significantly higher in the non-responders before treatment. Cell type enrichment analysis showed that differentially expressed genes (DEGs) between responders and non-responders were enriched in monocytes. Gene set enrichment analysis, together with single-cell analysis and deconvolution analysis, identified that Toll-like receptor 5 (TLR5) and interleukin-17 receptor A (IL17RA) pathway in monocytes was upregulated in non-responders. Hepatocyte growth factor (HGF) correlated with this signature showed higher concentrations in non-responders before treatment. The DEGs in the replication set were also enriched for the genes expressed in monocytes, not for the TLR5 and IL17RA pathway but for the oxidative phosphorylation (OXPHOS) pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Monocyte-derived transcriptomic features before treatment underlie the differences in abatacept efficacy in patients with RA. The pathway activated in monocytes was the TLR5 and IL17RA-HGF signature in the current study, while it was the OXPHOS pathway in the replication set. Elevated levels of HGF before treatment may serve as a potential biomarker for predicting poor responses to abatacept. These findings provide insights into the biological mechanisms of abatacept resistance, contributing valuable evidence for stratifying patients with RA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03236-y","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T06:02:37Z","timestamp":1704175357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis"],"prefix":"10.1186","volume":"26","author":[{"given":"Takeshi","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"3236_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"3236_CR2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"3236_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67:547\u201354.","journal-title":"Ann Rheum Dis"},{"key":"3236_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75:709\u201314.","journal-title":"Ann Rheum Dis"},{"key":"3236_CR5","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canh\u00e3o H, et al. Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol. 2016;68:1346\u201352.","journal-title":"Arthritis Rheumatol"},{"key":"3236_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1620\/tjem.250.153","volume":"250","author":"S Okazaki","year":"2020","unstructured":"Okazaki S, Watanabe R, Harigae H, Fujii H. Better retention of abatacept is associated with high rheumatoid factor: a five-year follow-up study of patients with rheumatoid arthritis. Tohoku J Exp Med. 2020;250:153\u20139.","journal-title":"Tohoku J Exp Med"},{"key":"3236_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/rheumatology\/kev417","volume":"55","author":"P Gazeau","year":"2016","unstructured":"Gazeau P, Devauchelle-Pensec V, Pochard P, Pers JO, Saraux A, Renaudineau Y, et al. Abatacept efficacy in rheumatoid arthritis is dependent upon baseline blood B-cell levels. Rheumatology (Oxford). 2016;55:1138\u201340.","journal-title":"Rheumatology (Oxford)"},{"key":"3236_CR8","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3899\/jrheum.110386","volume":"38","author":"M Scarsi","year":"2011","unstructured":"Scarsi M, Ziglioli T, Airo P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2105\u201311.","journal-title":"J Rheumatol"},{"key":"3236_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13075-020-2137-y","volume":"22","author":"W Yokoyama-Kokuryo","year":"2020","unstructured":"Yokoyama-Kokuryo W, Yamazaki H, Takeuchi T, Amano K, Kikuchi J, Kondo T, et al. Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22:46.","journal-title":"Arthritis Res Ther"},{"key":"3236_CR10","first-page":"1234","volume":"77","author":"K Oryoji","year":"2018","unstructured":"Oryoji K, Yoshida K, Kashiwado Y, Tanaka K, Mizuki SI, Tsukamoto H, et al. Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis. Ann Rheum Dis. 2018;77:1234\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3236_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"A Frank","year":"1988","unstructured":"Frank A, Steven E, Daniel B, Dennis M, James F, Norman C, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"3236_CR12","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3236_CR13","doi-asserted-by":"crossref","unstructured":"Van Gestel AM, Prevoo MLL, Van \u2019T Hof MA, Van Rijswijk MH, Van De Putte LBA, Van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34\u201340.","DOI":"10.1002\/art.1780390105"},{"key":"3236_CR14","doi-asserted-by":"publisher","first-page":"901437","DOI":"10.3389\/fimmu.2022.901437","volume":"13","author":"T Iwasaki","year":"2022","unstructured":"Iwasaki T, Watanabe R, Ito H, Fujii T, Okuma K, Oku T, et al. Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis. Front Immunol. 2022;13:901437.","journal-title":"Front Immunol"},{"key":"3236_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3236_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"key":"3236_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3236_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3236_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"3236_CR20","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"3236_CR21","doi-asserted-by":"publisher","first-page":"W782","DOI":"10.1093\/nar\/gkac392","volume":"50","author":"Y Dai","year":"2022","unstructured":"Dai Y, Hu R, Liu A, Cho KS, Manuel AM, Li X, et al. WebCSEA: web-based cell-type-specific enrichment analysis of genes. Nucleic Acids Res. 2022;50:W782\u201390.","journal-title":"Nucleic Acids Res"},{"key":"3236_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/humu.23230","volume":"38","author":"S Kawaguchi","year":"2017","unstructured":"Kawaguchi S, Higasa K, Shimizu M, Yamada R, Matsuda F. HLA-HD: An accurate HLA typing algorithm for next-generation sequencing data. Hum Mutat. 2017;38:788\u201397.","journal-title":"Hum Mutat"},{"key":"3236_CR23","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1136\/annrheumdis-2011-200353","volume":"70","author":"C Terao","year":"2011","unstructured":"Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, et al. A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Ann Rheum Dis. 2011;70:2134\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3236_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-016-1052-8","volume":"18","author":"S Nakamura","year":"2016","unstructured":"Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, et al. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Res Ther. 2016;18:159.","journal-title":"Arthritis Res Ther"},{"key":"3236_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-017-1319-8","volume":"19","author":"C Derambure","year":"2017","unstructured":"Derambure C, Dzangue-Tchoupou G, Berard C, Vergne N, Hiron M, D\u2019Agostino MA, et al. Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis. Arthritis Res Ther. 2017;19:109.","journal-title":"Arthritis Res Ther"},{"key":"3236_CR26","doi-asserted-by":"publisher","first-page":"724895","DOI":"10.3389\/fimmu.2021.724895","volume":"12","author":"C Triaille","year":"2021","unstructured":"Triaille C, Durez P, Sokolova T, Tilman G, de M\u00e9ricBellefon L, Galant C, et al. Common transcriptomic effects of abatacept and other DMARDs on rheumatoid arthritis synovial tissue. Front Immunol. 2021;12:724895.","journal-title":"Front Immunol"},{"key":"3236_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47.","journal-title":"Nucleic Acids Res"},{"key":"3236_CR28","doi-asserted-by":"publisher","first-page":"e20211191","DOI":"10.1084\/jem.20211191","volume":"219","author":"B Zhang","year":"2022","unstructured":"Zhang B, Zhang Y, Xiong L, Li Y, Zhang Y, Zhao J, et al. CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases. J Exp Med. 2022;219:e20211191.","journal-title":"J Exp Med"},{"key":"3236_CR29","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20:928\u201342.","journal-title":"Nat Immunol"},{"key":"3236_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"3236_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jot.2020.10.011","volume":"27","author":"C Huang","year":"2021","unstructured":"Huang C, Zheng Y, Bai J, Shi C, Shi X, Shan H, et al. Hepatocyte growth factor overexpression promotes osteoclastogenesis and exacerbates bone loss in CIA mice. J Orthop Translat. 2021;27:9\u201316.","journal-title":"J Orthop Translat"},{"key":"3236_CR32","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/art.30163","volume":"63","author":"B Grandaunet","year":"2011","unstructured":"Grandaunet B, Syversen SW, Hoff M, Sundan A, Haugeberg G, Van Der Heijde D, et al. Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:662\u20139.","journal-title":"Arthritis Rheum"},{"key":"3236_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL. Structure and signalling in the IL-17 receptor superfamily. Nat Rev Immunol. 2009;9:556.","journal-title":"Nat Rev Immunol"},{"key":"3236_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4049\/jimmunol.1102977","volume":"189","author":"ND Chamberlain","year":"2012","unstructured":"Chamberlain ND, Vila OM, Volin MV, Volkov S, Pope RM, Swedler W, et al. TLR5; a novel and unidentified inflammatory mediator in Rheumatoid Arthritis that correlates with disease activity score and joint TNF-\u03b1 levels. J Immunol. 2012;189:475.","journal-title":"J Immunol"},{"key":"3236_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/25785826.2020.1756609","volume":"43","author":"Y Iwasaki","year":"2020","unstructured":"Iwasaki Y, Takeshima Y, Fujio K. Basic mechanism of immune system activation by mitochondria. Immunol Med. 2020;43:142\u20137.","journal-title":"Immunol Med"},{"key":"3236_CR36","doi-asserted-by":"publisher","first-page":"703972","DOI":"10.3389\/fimmu.2021.703972","volume":"12","author":"MD Ch\u00e1vez","year":"2021","unstructured":"Ch\u00e1vez MD, Tse HM. Targeting mitochondrial-derived reactive oxygen species in T Cell-Mediated autoimmune diseases. Front Immunol. 2021;12:703972.","journal-title":"Front Immunol"},{"key":"3236_CR37","doi-asserted-by":"publisher","first-page":"e1237","DOI":"10.1002\/cti2.1237","volume":"10","author":"T McGarry","year":"2021","unstructured":"McGarry T, Hanlon MM, Marzaioli V, Cunningham CC, Krishna V, Murray K, et al. Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease. Clin Transl Immunology. 2021;10:e1237.","journal-title":"Clin Transl Immunology"},{"key":"3236_CR38","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/cells10081860","volume":"10","author":"L Roszkowski","year":"2021","unstructured":"Roszkowski L, Ciechomska M. Tuning monocytes and macrophages for personalized therapy and diagnostic challenge in rheumatoid arthritis. Cells. 2021;10:1860.","journal-title":"Cells"},{"key":"3236_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:17\u201333.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03236-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T06:09:56Z","timestamp":1704175796000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3236"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03236-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"27 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was performed following the Helsinki Declaration and was approved by the Kyoto University Graduate School and Faculty of Medicine Ethics Committee (approval number: G0511). Written informed consent to participate in the present study and publish the results obtained was provided by all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ryu Watanabe has received a research grant from AbbVie and speaker\u2019s fee from Asahi Kasei, Chugai, Eli Lilly, and GSK. Hiromu Ito received Grant\/research support from Bristol Myers. Takayuki Fujii received Speakers bureau from Asahi Kasei Pharma, Abbvie, Jansen, Tanabe Mitsubishi Pharma, and Eisai Co LTD. Koichi Murata received speakers bureau from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd., and Asahi Kasei Pharma Corp., Grant\/research support from: Daiichi Sankyo Co. Ltd. Kosaku Murakami received speakers bureau from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., Astellas Pharma Inc., UCB Japan Co. and Asahi Kasei Pharma Corp. Akira Onishi received Speakers bureau: Pfizer Inc., Bristol-Myers Squibb., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., Abbvie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd., Grant\/research support from: Pfizer Inc., Bristol-Myers Squibb., Advantest, Ayumi, and the Health Care Science Institute., Employee of: Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan, and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). It is also supported by grants from Daiichi Sankyo Co. Ltd. Above-mentioned pharmaceutical companies were not involved in the study design, data collection and analysis, manuscript writing, and manuscript submission. Masao Tanaka received speakers bureau from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Tanabe Mitsubishi Pharma Corp., UCB Japan Co., Ltd., Grant\/research support from: AbbVie GK, Kyowa Kirin Co., Ltd. Taisho Pharmaceutical Co., Ltd. Teijin Pharma, Ltd, Employee of: M.T. belongs to the department financially supported by two local governments in Japan (Nagahama City, Shiga and Toyooka City, Hyogo) and two pharmaceutical companies (Ayumi Pharmaceutical Corp., Asahi Kasei Pharma Corp.)., Akio Morinobu received speakers bureau from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., and Gilead Sciences Japan., Grant\/research support from: AbbVie G.K., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co. Taisho Pharmaceutical Co., Ltd.,and Eisai Co. Ltd. outside the work., Motomu Hashimoto received speakers bureau from Eli Lilly, Chugai, Mitsubishi Tanabe, Bristol Myers, Eisai, Grant\/research support from: AbbVie, Asahi Kasei, Astellas, Bristol Myers, Eisai, Daiichi Sankyo, Eli Lilly, Novartis, Eisai, Taisho Toyama. No other author declares a competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}